Dilon secures sales and marketing financing
Dilon Technologies LLC, a U.S. manufacturer and supplier of high-resolution molecular imaging systems recently completed an equity offering of $7.25 million that will propel the company's sales and marketing efforts. The deal was placed by Taglich Brothers Inc. of New York, NY, a full-service investment banking firm focused exclusively on microcap companies.
"The capital infusion provides funding for the advancement of our national sales operations and international business ventures," said Lon Slane, president of Dilon Technologies. Having Dilon has sold gamma cameras -- optimized for breast cancer diagnosis -- across the US and into Europe, and has installations pending in Canada and Israel. The company’s growth requires this additional funding to support demand and the company's growth, Slane added.
Breast-Specific Gamma Imaging (BSGI) is the novel imaging technique enabled by Dilon's dedicated camera. This diagnostic test provides a functional imaging component to breast cancer detection not found in other types of breast imaging: such as mammography, ultrasound and MRI, the company said.
"The capital infusion provides funding for the advancement of our national sales operations and international business ventures," said Lon Slane, president of Dilon Technologies. Having Dilon has sold gamma cameras -- optimized for breast cancer diagnosis -- across the US and into Europe, and has installations pending in Canada and Israel. The company’s growth requires this additional funding to support demand and the company's growth, Slane added.
Breast-Specific Gamma Imaging (BSGI) is the novel imaging technique enabled by Dilon's dedicated camera. This diagnostic test provides a functional imaging component to breast cancer detection not found in other types of breast imaging: such as mammography, ultrasound and MRI, the company said.